The costs of alcoholism

References

• Agosti, V. (1994). The efficacy of controlled trials of alcohol misuse treatments in maintaining abstinence: A meta-analysis. International Journal of the Addictions, 29, 759–769.
   PubMed Web of Science ®Google Scholar
• Annemans, L., Vanoverbeke, N., Tecco, J., & D'Hooghe, D. (2000). Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. European Addiction Research, 6, 71 — 78.
   Google Scholar
• Brecht, J. G., Poldrugo, F., & Schädlich, P. K. (1996). Alcoholism: The cost of illness in the Federal Republic of Germany. Pharmacoeconomics, 10, 484–493.
   Google Scholar
• Centers for Disease Control and Prevention (1990). Perspectives in disease prevention and health promotion. Alcohol-related mortality and years of potential life lost. Morbidity and Mortality Weekly Report, 39, 173–178.
   PubMedGoogle Scholar
• Cisler, R., Holder, H. D., Longabaugh, R., Stout, R L., & Zweben, A. (1998). Actual and estimated replication costs for alcohol treatment modalities: Case study from Project MATCH. Journal of Studies on Alcohol, 59, 503–512.
   Google Scholar
• Coyle, D., Godfrey, C., Hardman, G., & Raistrick, D. (1997). Costing substance misuse services. Addiction, 92, 1007–1015.
   PubMed Web of Science ®Google Scholar
• Foster, R. H., & McClellan, K. J. (1999). Acamprosate: pharmacoeconomic implications of therapy. Pharmacoeconomics, 16, 743–755.
   PubMed Web of Science ®Google Scholar
• Gatch, M. B., & Lal, H. (1998). Pharmacological treatment of alcoholism. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 22, 917–944.
   PubMed Web of Science ®Google Scholar
• Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999). Pharmacological treatment of alcohol dependence: A review of the evidence. Journal of the American Medical Association, 281, 1318–1325.
   PubMed Web of Science ®Google Scholar
• Goodman, A. C., Nishiura, E., & Humphreys, R. S. (1997). Cost and usage impacts of treatment initiation: a comparison of alcoholism and drug abuse treatments. Alcoholism: Clinical & Experimental Research, 21, 931 — 938.
   Web of Science ®Google Scholar
• Gossop, M. (1995). The treatment mapping survey; a descriptive study of drug and alcohol treatment responses in 23 countries. Drug & Alcohol Dependence, 39, 7–14.
   PubMed Web of Science ®Google Scholar
• Harwood, H. J., Fountain, D., & Livermore, G. (1998). Economic costs of alcohol abuse and alcoholism. Recent Developments in Alcoholism, 14, 307–330.
   PubMedGoogle Scholar
• Hayashida, M., Alterman, A. I., McLellan, A. T., O'Brien, C. P., Purtill, J. J., Volpicelli, J. R., et al. (1989). Comparative effectiveness and costs of inpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. New England Journal of Medicine, 320, 358–365.
   Google Scholar
• Holder, H. D. (1987). Alcoholism treatment and potential health care cost saving. Medical Care, 25, 52-71. Holder, H. D., Longabaugh, R., Miller, W. R., & Rubonis, A. V. (1991). The cost effectiveness of treatment for alcoholism: A first approximation. Journal of Studies on Alcohol, 52, 517–539.
   Google Scholar
• Holder, H. D., & Blose, J. O. (1992). The reduction of health care costs associated with alcoholism treatment: A 14-year longitudinal study. Journal of Studies on Alcohol, 53, 293— 302.
   PubMedGoogle Scholar
• Holder, H. D., Cisler, R. A., Longabaugh, R., Stout, R. L., Treno, A., & Zweben, A. (2000). Alcoholism treatment and medical care costs from Project MATCH. Addiction, 95, 999— 1013.
   PubMed Web of Science ®Google Scholar
• Howard, M. O., McGuffin, R. W., Saxon, A. J., Sloan, K. L., & Walker, R D. (1996). Clinical issues related to the costs of alcoholism. Pharmacoeconomics, 9, 134–145.
   Google Scholar
• Long, C. G., Williams, M., & Hollin, C. R. (1998). Treating alcohol problems: A study of programme effectiveness and cost effectiveness according to length and delivery of treatment. Addiction, 93, 561 —571.
   Web of Science ®Google Scholar
• Mason, B. J. (2003). Acamprosate and naltrexone treatment for alcohol dependence: An evidence-based risk-benefit assessment. European Neuropsychopharmacology, 13, 469–475.
   PubMed Web of Science ®Google Scholar
• McCollister K. E., & French M. T. (2003) The relative contribution of outcome domains in the total economic benefit of addiction interventions: A review of first findings. Addiction, 98, 1647–1659.
   PubMed Web of Science ®Google Scholar
• McLellan, A. T., SE Hunkeler E. (1998). Patient satisfaction and outcomes in alcohol and drug abuse treatment. Psychiatric Services, 49, 573— 575.
   Google Scholar
• McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness. Journal of the American Medical Association, 284, 1689–1695.
   Google Scholar
• Moncini, M., Masini, E., Gambassi, F., & Mannaioni, P. F. (2000). Gamma-hydroxybutyric acid and alcohol-related syndromes. Alcohol, 20, 285–291.
   PubMed Web of Science ®Google Scholar
• Office of Population Censuses and Surveys (1995). The prevalence of psychiatric morbidity among adults living in private households in Great Britain. London: HMSO.
   Google Scholar
• Palmer, A. J., Neeser, K., Weiss, C., Brandt, A., Comte, S., & Fox, M. (2000). The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol and Alcoholism, 35, 478–492.
   PubMed Web of Science ®Google Scholar
• Parthasarathy, S., Weisner, C., Hu, T. W., & Moore, C. (2001). Association of outpatient alcohol and drug treatment with health care utilization and cost: revisiting the offset hypothesis. Journal of Studies on Alcohol, 62, 89 — 97.
   PubMedGoogle Scholar
• Sass, H., Soyka, M., Mann, K., & Zieglgansberger, W. (1996). Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry, 53, 673— 680
   Web of Science ®Google Scholar
• Schädlich, P. K., & Brecht, J. G. (1998). The cost effectiveness of Acamprosate in the treatment of alcoholism in Germany: Economic evaluation of the prevention of relapse with acamprosate in the management of alcoholism (PRAMA) study. Phannacoeconomics, 13, 719–730.
   Google Scholar
• Schmidt, L. G., Dufeu, P., Kuhn, S., & Rommelspacher, H. (1994). Relapse prevention in alcoholics with an anticraving drug treatment: first results of the Berlin Study. Pharmacopsychiatry, 27 (Suppl.), 1–3.
   Google Scholar
• Srisurapanont, M., & Jarusuraisin, N. (2001). Opioid antagonists for alcohol dependence (Cochrane Review). In: The Cochrane Library, Issue 4, Oxford: Update Software.
   Google Scholar
• Weisner, C., Mertens, J., Parthasarathy, S., Moore, C., Hunkeler, E. M., Hu, T., & Selby, J. V. (2000). The outcome and cost of alcohol and drug treatment in an HMO: Day hospital versus traditional outpatient regimens. Health Services Research, 35, 791 — 812.
   PubMed Web of Science ®Google Scholar
• West, S. L., Garbutt, J. C., Carey, T. S. et al. (1999). Phannacotherapy for alcohol dependence. AHCPR Publication No. 99-E004, Rockville, MD, USA.
   Google Scholar
• Whitworth, A. B., Fisher, F., Lesch, O. M., Nimmerrichter, A., Oberbauer, H., Platz, F., et al. (1996). Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet, 347, 1438–1442
   PubMed Web of Science ®Google Scholar